Company intelligence / Profile preview

Ksilink

Strasbourg, Grand Est, Franceksilink.com ↗

Ownership: Private
Employees: ~21
Development stage: Preclinical

Overview

Ksilink has established proof-of-concept for its platform and operates a pipeline of proprietary programs in muscular/neurologic diseases and oncology. The company’s approach aims to derisk early-stage drug candidates using advanced patient-based disease modeling with AI-powered analytics. No clinical results are reported yet; the focus remains preclinical.

Therapeutic areas: OncologyNeurology
Modalities: Patient-derived cellular modelssmall moleculesAI-driven phenotypic screening
Industry: Biotech

Partnerships

InsermSanofi

Beyond the preview

Go deeper on Ksilink.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ksilink.

Explore the full profile